SKSvitlana Kustova

Svitlana Kustova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Svitlana Kustova has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • I. V. Volokhov

    SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Alchevskykh str., 10; National University of Pharmacy, Hryhorii Skovoroda str., 53, Kharkiv

    4 shared publications
  • Viktoria Rybak

    National University of Pharmacy

    4 shared publications
  • Loriana Sergienko

    SI «V. Danilevsky Institute for Endocrine pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine

    3 shared publications
  • S. S. Sokolova

    ДУ «Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України», Харків, Україна

    3 shared publications
  • Inna Bielkina

    SI «V. Danilevsky Institute for Endocrine pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine

    2 shared publications
  • M. O. Boiko

    ДУ «Інститут проблем ендокринної патології ім. В. Я. Данилевського НАМН України», Національний фармацевтичний університет

    2 shared publications

Latest Publications

  • Open Access

    ДОСЛІДЖЕННЯ ВПЛИВУ ФАРМАЦЕВТИЧНОЇ КОМПОЗИЦІЇ НА ОСНОВІ ЛІВОКАРНІТИНУ НА СТРУКТУРНО-ФУНКЦІОНАЛЬНИЙ СТАН ЩИТОПОДІБНОЇ ЗАЛОЗИ ВАГІТНИХ ЩУРІВ ПРИ ПАСИВНОМУ КУРІННІ

    by І. В. Волохов, В. А. Рибак, Л. Ю. Сергієнко, С. С. Соколова, С. П. Кустова, М. О. Бойко

    РЕЗЮМЕ. Несприятливим чинником навколишнього середовища є пасивне куріння, яке сприяє ризику виникнення тиреоїдної патології серед вагітних. Мета – оцінити гістологічну будову щитоподібної залози та забезпечення тиреоїдними гормонами організму вагітних щурів під впливом фармацевтичної композиції на основі лівокарнітину на тлі моделювання пасивного куріння. Матеріал і методи. Дослідження проведено на 40 нелінійних вагітних щурах 6-місячного віку, складовими якого є такі експериментальні етапи: спаровування тварин, встановлення першого дня вагітності, моделювання пасивного куріння та введення досліджуваних речовин (препарат порівняння кардонат, фармацевтична композиція на основі лівокарнітину) піддослідним групам під час вагітності, автопсія вагітних щурів на 20 день гестації з подальшою оцінкою гістоструктури щитоподібної залози та визначенням рівня тиреоїдних гормонів у сироватці крові. Результати. Вплив пасивного куріння під час вагітності проявляється негативними змінами у гістоструктурі щитоподібної залози: збільшенням розмірів фолікулів, сплющеною формою тиреоцитів фолікулярного епітелію, вираженням міжчасточкових прошарків сполучної тканини, підвищеною повнокровністю судин мікроциркуляторного русла, зменшенням обсягу інтрафолікулярного епітелію. Також унаслідок впливу пасивного куріння під час вагітності спостерігається підвищення рівня тиреоїдних гормонів у сироватці крові. Застосування фармацевтичної композиції на основі лівокарнітину у вагітних щурів на тлі моделювання пасивного куріння знижує рівень тиреоїдних гормонів та зменшує морфологічні ознаки структурних порушень щитоподібної залози, які були виявлені у щурів групи пасивного куріння. Висновки. Встановлено структурно-функціональні особливості щитоподібної залози у вагітних щурів при моделюванні пасивного куріння, які характеризуються гістологічними ознаками помірного зниження здатності паренхіми органа до репаративних процесів та утворення нових фолікулів з одночасним зростанням тиреоїдних гормонів у сироватці крові. Застосування фармацевтичної композиції на основі лівокарнітину в дозі 25 мг/кг при моделюванні пасивного куріння під час вагітності сприяє збереженню нормальної гістоструктури щитоподібної залози та запобігає надмірному підвищенню тиреоїдних гормонів за умов дії продуктів згорання сигарет.

  • Open Access

    The effect of pharmaceutical composition based on L-carnitine on structural and functional features of rat placenta in the model of passive tobacco smoking

    by I.V. Volokhov, V.A. Rybak, L.YU. Sergienko, S.S. Sokolova, S.P. Kustova

    Passive tobacco smoking in modern society is quite common phenomenon. Maternal smoking, including passive smoking, is one of the modifying risk factors for adverse pregnancy outcomes and is associated with disorders of the pregnant woman's reproductive system, including the development of placental dysfunction. The aim of this study was to investigate the effect of a pharmaceutical composition based on L-carnitine on the structural and functional features of the rat placenta in a model of passive tobacco smoking. The study was conducted on 40 nonlinear pregnant rats aged 6 months. Passive smoking modeling was performed from day 1 to day 20 of pregnancy. From the first day of gestation, daily for 20 days, rats were intragastrically administered a pharmaceutical composition based on L-carnitine at an effec­tive dose of 25 mg/kg, and rats of the positive control group received the reference drug at a dose of 68 mg/kg. On the 20th day of pregnancy, the animals were withdrawn from the experiment to study the microstructure of the placenta and determine the level of sex hormones. Structural and functional changes in the rat placenta in the model of passive tobacco smoking were determined. The gravidoprotective effect of the pharmaceutical composition based on L-carnitine at a dose of 25 mg/kg in pregnant rats with a reproduced model of passive smoking was proved, which was manifested by a decrease in histomorphological and hormonal signs of fetoplacental insufficiency compared to the negative control. The gravidoprotective effect in rats treated with a pharmaceutical composition based on L-carnitine and exposed to passive smoking was manifested by a significant decrease in the severity of negative changes in the placental histological structure, which were recorded in animals from the passive smoking group, as evidenced by the following signs of increased width of the labyrinthine section normal width of the decidual membrane, no expansion of blood-filled lacunae, sufficient contact area of fetal and maternal vessels, no signs of thrombosis in maternal lacunae, the predominant number of fetal capillaries without signs of hemostasis with normal blood filling and wall thickness. The use of a pharmaceutical composition based on L-carnitine at a dose of 25 mg/kg in pregnant rats with a reproduced model of passive smoking reduces the damaging effect of cigarette combustion products on placental steroidogenesis. This is manifested by a less pronounced decrease in progesterone levels by 22.47% and free estriol by 55.48% compared to animals exposed to passive smoking, which almost corresponds to the activity of the reference drug at a dose of 68 mg/kg. The presence of a gravidoprotective effect of the pharmaceutical composition based on L-carnitine indicates the prospects for further pharmacological studies to prevent and treat the negative effects of fetoplacental insufficiency on the mother and fetus caused by placental hypoxia due to tobacco smoking.


  • Open Access

    HISTOSTRUCTURE OF THE KIDNEYS OF RATS WHOSE MOTHERS RECEIVED A PHARMACEUTICAL COMPOSITION BASED ON L-CARNITINE DURING PREGNANCY WITH PASSIVE TOBACCO SMOKING

    by I. V. Volokhov, V. А. Rybak, L. Yu. Sergienko, S. S. Sokolova, S. P. Kustova

    Introduction. Passive tobacco smoking is an unfavorable environmental factor, which remains quite common among pregnant women. Nicotine reduces the activity of uteroplacental circulation, which leads to fetal hypoxia that is the pathogenetic basis of structural changes in the kidneys and the risk of developing kidney disease in the periods of life remote from birth. The aim of the study is to investigate the histostructural features of the kidneys in the offspring of mothers who received a pharmaceutical composition based on L-carnitine in the modeling of passive smoking during pregnancy. Materials and methods. The following experimental stages were carried out: modeling of passive smoking and administration of the test substances to the experimental groups during pregnancy, autopsy of offspring at the age of 11 months with further assessment of histostructural features of the kidneys. Results. The effect of passive tobacco smoking during fetal development on the histostructural features of the kidneys is manifested in mature rats by negative signs: reduction in the number and size of renal corpuscles, increase in the lumen of the capsule of Shumlansky- Bowman and the diameter of the lumen of convoluted tubules, reduction in the diameter of the afferent arteriole, arteriosclerosis, as well as pronounced foci of protein dystrophy of the epithelium of the convoluted tubules of the cortex, characterized by increased nephrocyte desquamation and the formation of protein cylinders in the lumen of convoluted tubules. The nephroprotective effect of a pharmaceutical composition based on L-carnitine at a dose of 25 mg/kg in offspring of mothers with a reproduced model of passive smoking during pregnancy was proved, as a decrease in negative changes in renal histology was observed, as evidenced by the presence of only small foci of protein dystrophy, as well as the dynamics of approaching histostructural parameters of the renal parenchyma of the intact control group. Проведено дослідження гістоструктурних особливостей нирок нащадків щурів, матері яких під час вагітності зазнавали впливу пасивного тютюнопаління та отримували фармацевтичну композицію на основі лівокарнітину. Вплив пасивного тютюнопаління під час внутрішньоутробного розвитку на гістоструктуру нирок у зрілому віці проявляється негативними ознаками: зменшенням ниркових тілець та діаметра приносної артеріоли, збільшенням просвіту капсули Шумлянського-Боумена та діаметра просвіту звивистих канальців, білковою дистрофією епітелію канальців, артеріолосклерозом. Застосування фармацевтичної композиції на основі лівокарнітину під час вагітності за умов моделювання пасивного тютюнопаління у матерів призводить до значного зменшення вираженості негативних змін гістоструктури нирок у нащадків.

  • Open Access

    FERTILITY FACTORS. D-HORMONE IN PREVENTION OF REPRODUCOPATHIES CAUSED BY BENIGN PROSTATIC HYPERPLASIA (Literature review)

    by Yevgenia Koreneva, Volodymyr Bondarenko, Nataliia Brechka, Natalia Smolienko, Inna Belkina, Svitlana Kustova, Maryna Boiko, Yurii Karachentsev

    In accordance with the statistical data, the spreading of benign prostatic hyperplasia (BPH) is increasing, because modern stressful lifestyle causes sex hormones disbalances and other dyshormonal conditions which lead to pathologies’ development at younger ages. The pathogenesis of BPH is connected with disturbances of regulation in the hypothalamo-hypophyseal system and with the changes of the regulatory signals intensity which go to the reproductive organs. The central pathogenic links of this pathology’ development are: the declining of efficacy of hypothalamus functioning regulation which carries out on the basis of feedback; the changes of the pituitary gland cells sensitivity to the releasing hormones of hypothalamus and disbalance of sex hormones. In addition to gonadotropins prolactin has a significant impact on the BPH development. Its hypersecretion causes the development of hyperplastic age-related changes in prostate gland. The introduction of dopamine receptors antagonists such as sulpiride causes the increasing of prolactin concentration and declining of gonadotropins releasing. “Sulpiride model” is broadly used in the experimental endocrinology for studying prostate-active drugs and is characterized by sex hormones disbalance' and inflammation processes’ development. The development of the pathology is linked with the disturbance of testosterone synthesis in the testicles, insufficiency of prostate gland functioning and increasing of prolactin and estradiol concentrations which provoke proliferative changes. The androgens disbalance is the main cause of BHP development, therefore, the “Testosterone model” based on testosterone’ and estradiol’ slow releasing implants is broadly used for modeling of urination disturbance in rats which imitates the same condition in elderly men with benign prostatic hyperplasia. The prostatitis, which developed under the condition of BHP, causes the disturbances of spermatogenesis during experimental modeling and in the clinical practice when spermatopathies, sexual disturbances and hypofertility are diagnosed in patients. The traditional BHP therapeutic methods are not always effective and the new therapeutic approaches of hypofertility caused by prostate gland pathologies are developed by investigators. Thus, there are data about correlation between increased vitamin D consumption and decreasing of BHP spreading, between gland volume and cells proliferation in patients with this pathology. Vitamin D level influences the quantity and quality of ejaculate. The deficiency of vitamin D is associated with lower proportion of sex hormones in young men and choriogonin sensitivity of Leydig's cells to be diminished. It has been experimentally shown that cholecalciferol regulates steroid hormones genesis, mitigates the age-related declining of testicles activity, protects the testicles in old animals and the unchanged spermatogenesis in normal males which received vitamin D3 can be considered to be the result of estrogens and androgens balance. The androgens receptors as well as vitamin D receptors have been found in prostate gland in health males and in those with hyperplasia. In addition to its classical function in calcium homeostasis and bones health, vitamin D inhibits tumor growth in different tissues including prostate gland. Vitamin D metabolites have been determined to be anti-inflammatory, proapoptotic and antiproliferative. D-hormone application potentiates the specific properties of prostate gland protectors, recovers reproductive capacity under the condition of experimental chronic prostatitis of inflammatory genesis as well as traumatic. All facts listed above allow to confirm the positive role of D-hormone in the regulation of prostate gland and reproductive function in patients with BHP and recovering of fertility under the condition of this pathology. The literature search for this review has been carried out on databases PubMed, Science Direct, Europa PMC, BMC, MedLine etc.


  • Open Access

    СКРИНІНГОВІ ДОСЛІДЖЕННЯ АНТИГІПОКСИЧНИХ ВЛАСТИВОСТЕЙ ФАРМАЦЕВТИЧНОЇ КОМПОЗИЦІЇ НА ОСНОВІ ЛІВОКАРНІТИНУ ДЛЯ КОРЕКЦІЇ НАСЛІДКІВ ФЕТОПЛАЦЕНТАРНОЇ НЕДОСТАТНОСТІ

    by I. V. Volokhov, V. A. Rybak, L. Yu. Sergienko, S. P. Kustova, T. V. Matvieieva, T. V. Bondarenko, M. O. Boiko

    Мета роботи: становити антигіпоксичні властивості фармацевтичної композиції на основі лівокарнітину. Матеріали та методи. Дослідження антигіпоксичних властивостей фармацевтичної композиції на основі лівокарнітину проведено на двох експериментальних моделях гострої гіпоксії, відтворених на нелінійних мишах-самцях (Mus musculus). Щоденно впродовж 15 діб та за годину до проведення тестів із визначення антигіпоксичної дії тваринам вводили ФК на основі лівокарнітину, а мишам групи позитивного контролю – референтний препарат – мексикор. Ефективність дії фармацевтичної композиції на основі лівокарнітину на експериментальних моделях гіпоксії визначено за показниками: коефіцієнт антигіпоксичної активності, середня тривалість життя тварин та відносна антигіпоксична активність. Результати й обговорення. Встановлено, що фармацевтична композиція на основі лівокарнітину в дозі 25 мг/кг на моделі гострої нормобаричної гіпоксії з гіперкапнією проявляє найбільшу антигіпоксичну активність, яка становить – 31 %, що відповідає активності препарату порівняння мексикор у дозі 16 мг/кг. На моделі гострої гемічної гіпоксії визначено більш виражену антигіпоксичну активність фармацевтичної композиції на основі лівокарнітину у дозі 25 мг/кг, яка становить 41 % та є дещо вищою порівняно із мексикором у дозі 16 мг/кг. Висновки. Визначено, що ФК на основі лівокарнітину у дозі 25 мг/кг при внутрішньошлунковому введенні мишам проявляє найбільш виражену антигіпоксичну дію на моделі гострої гемічної гіпоксії, порівняно із референс-препаратом мексикор у дозі 16 мг/кг (41 % проти 33 %). Профілактичне введення фармацевтичної композиції на основі лівокарнітину у дозі 25 мг/кг підвищує стійкість тварин до гіпоксичних станів. Встановлено виражену антигіпоксичну активність фармацевтичної композиції на основі лівокарнітину на моделі гострої гемічної гіпоксії, що зумовлює перспективність подальших фармакологічних досліджень для застосування в медичній практиці з метою профілактики наслідків фетоплацентарної недостатності.

  • Open Access

    THE IMPACT OF CHOLECALCIFEROL ON THE SEX HORMONES LEVEL AND SERUM BIOCHEMICAL INDICES IN RAT MALES WITH EXPERIMENTAL GONADOPATHY

    by Inna Bielkina, Natalia Velychko, Ihor Marakhovskyi, Yevheniia Korenieva, Natalia Smolienko, Elina Chystiakova, Natalia Brechka, Marina Boiko, Svitlana Kustova, Volodymyr Bondarenko

    The testicular deficiency, cryptorchidism, varicocele, endocrine pathologies are the main causes of men infertility. The internal diseases of testicles lead to fertility declining in the major part of cases which explains the importance of studying of gonadopathies᾿ methods of correction. In recent times, vitamin D is noted among remedies suitable for effective correction of reproductive system. The aim of investigation: to determine the sex hormones levels and biochemical indices in serum of rats’ males with experimental testicles damage under the condition of vitamin D3 correction used separately or in combination with Tribestan®. Materials and methods. The experiment has been carried out on mature Vistar rats’ males; group of animals: S-model (animals with serotonin-induced gonads damage, gonadopathy (GP)); S+solvent (rats with gonadopathy which received solvent); S+vit. D3 (animals with gonadopathy received vitamin D3); S+Tr (rats with gonadopathy obtained Tribestan (Tr) – reference medicine); S+vit. D3+Tr (animals received both remedies); control – intact males. The activity of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), general content of nitrogen oxide cycle metabolites (NОх), concentration of TBARS and sex hormones Ts and E2 have been determined; their ratio has been calculated. Results. The NOх was increased in S-model rats. The application of vit. D3 or Tr has caused decreasing of NOх concentration in comparison with S-model group. The complex using of vit. D3 and Tr has had positive effect as for protection against oxidative stress (OS). The concentration of NOx in rats of S+vit. D3+Tr was by 56% less than in S-model group, but, as in the other experimental groups of animals, has remained increased relative to control group. The deficiency of free arginine in blood serum has been detected in all experimental groups comparing with Control group. The application of vit. D3 hasn’t affected on the arginine content. Tr has positively influenced the arginine level: the increasing of concentration of this amino acid was 95% relative to S-model group, but was less by 48% than values of intact animals. After application of Tr and vit. D3 together the concentration of arginine was higher by 2.2 times than in rats of S-model group, but hasn’t reached the values of intact animals. The concentration of TBARS has increased under the condition of GP. The using of vit. D3 has led to reducing, but not to normalizing of TBARS content. The concentration of TBARS in rats of S+Tr group was by 1.9 times lower than in rats with GP and by two times higher than in intact animals. Simultaneous using of Tr and vit. D3 has been effective as for reducing of lipid peroxidation (LP) intensity. The concentration of TBARS in S+vit. D3+Tr group has declined by 2.2 times comparing with values of animals with GP. The combination of Tr and vitamin D3 was more effective than cholecalciferol single using as for protection against OS and LP reducing and has demonstrated activity at the level of reference drug. GP has led to increasing of ALT activity 2.4 times and AST – by 2 times comparing with control group. The application of Tr, vit. D3 or their complex hasn’t changed ALT activity which was statistically higher than intact animals’ values. The activity of AST was increased in animals with GP and reduced after experimental correction of GP consequences. Vitamin D3 monotherapy has reduced by 32% the activity of AST comparing with animals with GP. AST concentration in males’ blood serum was decreased too with the combined use of Tr and vitamin D3 comparing with untreated animals. Thus, vitamin D has positively impacted the AST level in combined use with Tr as well as monotherapy. Serotonin-induced experimental GP has caused the declining of general Ts concentration in blood serum of animals of all experimental groups. The application of vitamin D3 hasn’t demonstrated androgen correcting activity. Tr has positively influenced androgen synthesized function: Ts concentration has increased by 95% comparing with S-model group, but remained lower by 31% than in intact animals. The Ts concentration in S+vit. D3+Tr group was 2.1 times higher than in animals with GP. However, Ts values in this group haven’t reached Control group values and were by 25% less. The concentration of estradiol in all experimental groups has corresponded to the values of intact animals. The calculation of Ts/Е2 ratio has shown to be decreased in S-model, S+solvent, S+vit. D3 groups in comparison with intact animals. The Ts/Е2 ratio has normalized in groups with GP treated by reference drug separately or in combination with vitamin D3. Conclusions: The application of cholecalciferol has considerably decreased NOx and TBARS concentrations, but hasn’t affected on arginine level which has declined with the gonadopathy. Vitamin D has caused reducing of aspartate aminotransferase activity in serum and hasn’t had androgenic and estrogenic effects. The application of Tribestan has led to the pro-oxidative/antioxidative balance recovery under the condition of experimental gonadopathy. This medicine has reduced the high level of aspartate aminotransferase activity, increased testosterone level and normalized testosterone/estradiol ratio in blood serum of experimental animals. The application of vitamin D and Tribestan in combination has led to improvement of androgenic status and has demonstrated better effect as for protection against oxidative stress and lipid peroxidation than cholecalciferol as a monotherapy.


  • Open Access

    The developing of medicine for prolonging the full-fledged activity of reproductive system

    by S. P. Kustova, M. O. Boiko, T. V. Matvieieva

    Development of the healthcare sector in Ukraine: the path towards the European Union (December 6–7, 2023. Częstochowa, the Republic of Poland) : International scientific conference. Riga, Latvia : Baltija Publishing, 2023. 100 pages.

  • Open Access

    THE REPRODUCTIVE PATHOLOGIES OF MALE OFFSPRING BORN TO MOTHERS WITH FETOPLACENTAL INSUFFICIENCY: HORMONE DEPENDENT MECHANISMS OF DEVELOPING AND PROFYLAXIS

    by Nataliia Seliukova, Kateryna Misiura, Svitlana Kustova, Maryna Boiko, Eugenia Korenieva, Myroslava Mykytyuk, Yurii Karachentsev

    Introduction. Fetoplacental insufficiency (FPI) is the symptom complex that substantially results not only in pregnancy development and childbirth, but in the health condition of offspring at different times. It has been shown that offspring born to mothers with FPI have morphological and functional disturbances of different systems of organs. The aims of this research were to determine hormone depended mechanisms of reproductive pathologies developing in the ontogenesis of male offspring born to different aged mothers with FPI and experimental grounding of potential preventive activity of developed pharmaceutical composition suitable for animals of this phenotype. Materials and methods. Mature Wistar rat females of young (3-4 months) and mature (8-10 months) reproductive age have been used in the experiment. Eights groups for 7 pregnant females in each group have been formed. Modeling of FPI has been carried out by daily subcutaneous administration of the 50 % tetrachloromethane oil solution at dose of 2 ml/kg of body weight from 12th to 18th day of pregnancy. The reproductive system of male offspring has been estimated. Results. FPI influences the sex differentiation of brain in male offspring that reflects in delaying of sexual maturity in the form of postponed testicles moving to the scrotum. FPI leads to relative estrogenization, inhibition of sperm cells differentiation and causes significant changes in antioxidant defense system in male offspring at puberty. FPI causes changes of testosterone, estradiol levels and shifts sex hormones ratio to the hyperestrogenemia in the all of mature male offspring that influence the activity of male sexual behavior, worsens spermogram and fertility. Conclusion. Fetoplacental insufficiency in females in third trimester of pregnancy leads to marked changes in reproductive system of their male offspring born to mothers of reproductively young and reproductively mature age. Data obtained indicate the opportunity and ways to develop the medicines for prophylaxis of reproductive pathologies in children born to mothers with fetoplacental insufficiency.

  • Open Access

    INVESTIGATION OF MICROSTRUCTURE OF INTERNAL ORGANS OF EXPERIMENTAL ANIMALS AFTER FENCUCINAL OINTMENT APPLICATIONS

    by L. Yu. Sergienko, Svitlana Kustova, M. Ya. Kudrya, O. V. Kartavtseva, G. M. Cherevko, Maryna Boyko, L. M. Tolmachova, M. V. Zhurakovskaya, T. O. Pavlenko

    Histological examinations of the microstructure of the internal organs of experimental animals were performed, which received ointment dermally for one month. fensuccinal at a dose of 2500 mg / kg body weight. Under these experimental conditions, no damaging effect of fensuccinal ointment on the organs of experimental animals was detected.